1 / 19

Philadelphia Chromosome

Philadelphia Chromosome. Importance in the oncologic diagnosis. Faculdade Medicina Universidade de Coimbra Biologia Celular e Molecular II 2012-2013. Elaborated by : José Duarte Luís Oliveira Pedro Pereira Turma 9. Introduction. Philadelphia chromosome (Ph)

arleen
Download Presentation

Philadelphia Chromosome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Philadelphia Chromosome Importance in theoncologicdiagnosis Faculdade Medicina Universidade de Coimbra Biologia Celular e Molecular II 2012-2013 Elaboratedby: José Duarte Luís Oliveira Pedro Pereira Turma 9

  2. Introduction • Philadelphia chromosome(Ph) • Discoveredin 1960 by Peter C. Noweland David Hungerford; • Firstoncological gene documented; • Advances in cytogenetics. In site http://articles.philly.com/2010-09-29/news/24980608_1_chromosome-chronic-myeloid-leukemia-leukemia-cells

  3. Origin • Resultsfrom a reciprocaltranslocation t(9;22) (q34;q11) • Defectivechromosome 22 isdesignated Philadelphia Chromosome • Quimerical gene BCR-ABL isproduced In site http://www.medicinageriatrica.com.br/tag/cromossomo-filadelfia/

  4. origin Normal Chromosomes Chromosomes Break ChangedChromosomes Changed Chromosome 9 Chromosome 9 Philadelphia Chromosome Chromosome 22 In site http://www.unesp.br/prope/projtecn/Saude/saude48a.htm

  5. Fusion gene • Increases the tyrosine-kinase activity of ABL; • Active; doesn’t need activation by other cellular messaging proteins; • Activates some cell cycle-controlling proteins and enzymes, speeding up cell division; • Inhibits DNA repair; • Increased proliferation in response to growth factors; • Increased resistance to apoptosis, and alteration of their adhesion properties. In site http://www.biologyreference.com/Oc-Ph/Oncogenes-and-Cancer-Cells.html

  6. Fusion gene Three distinct forms: p190BCR/ABL p210BCR/ABL p230BCR/ABL Leucemia

  7. leukemia Malignant tumor of bone marrow hematopoietic cells, that leads to the accumulation of the blast cells throughout the body. In site http://www.cancer.gov/cancertopics/pdq/treatment/CML/Patient/page1

  8. Cancers related to Philadelphia Chromosome Acute Myelogenous Leukemia (AML) Acute Lymphoblastic Leukemia (ALL) Chronic Myelogenous Leukemia (CML) The philadelphiachromosome is present in 95% of people with CML p210BCR/ABL 45–60% in adult and 80% in pediatric cases p190BCR/ABL Ph chromosome appears occasionally; most common in adults p230BCR/ABL Acute Lymphoblastic Leukemia (ALL) - 25–30% in adult and 2–10% in pediatric cases

  9. ClinicalPresentation Chronicmyelogenousleukemia - Thrombocytopenia; - Leukocytopenia; -Vulnerability to bruising, bleeding and infections; - Lymphadenopathy; - Splenomegaly; - Pain in the bones or joints. AcutelymphoblasticleukemiaPh (+) • Chronicphase(4-6 years): - Asymptomatic; - Thrombocytosis; - Leukocytosis; - Blast cell count less than 10%. • Acceleratedphase(18 months): - Splenomegaly; - Thrombocytopenia; - Leukocytosistreatmentresistant; -increasedblastcells (10-30%) in peripheral blood and bone marrow; - Clonalevolution. • Blastic /acutephase(survival 2-4mounths) - ≥ 30% blast cells in bone marrow; - More resistant to treatment. (Moralesetal, 2010)

  10. Diagnosis clinically oriented: Splenomegaly Hemogram (blasts, basophiles, eosinophils) Myelogram Bone marrow biopsy Referral to molecular and cytogenetic tests In site http://iahealth.net/acute-myeloid-leukemia/

  11. visualizationtechniques • Philadelphia chromosome identification: • Peripheral blood and bone marrow samples submitted to: • Kariotype analysis (gold standard) • FISH Chromosome Alterations • Southern Blotting • Traditional PCR • RT-PCR • RQ-PCR (high sensitivity) • Anchor-PET BCR/ABL transcripts identification and/or quantification

  12. visualizationtechniques KaryotypeAnalysis In site http://www.citogene.com.br/Citogenetica-De-Cancer.aspx

  13. visualizationtechniques Fluorescenthybridizationin situ (FISH) In site http://pt.wikipedia.org/wiki/Leucemia_mieloide_cr%C3%B4nica

  14. visualizationtechniques PolymeraseChainReaction (PCR) In site http://www.scielo.br/scielo.php?pid=S0104-42301998000300015&script=sci_arttext

  15. treatment Chemotherapy DonorLynphocyteinfusion Target Therapy BiologicalTherapy Surgery High Dose Chemotherapy with stem cells transplant

  16. Target Therapy • inhibitor of the • BCR-ABL tyrosine kinase

  17. Target Therapy Imatinib Mesylate Excelenttherapeuticeficiency Lowtoxicity Blocks ATP binding site of BCR-ABL Shorttimesideeffects Resistance to imatinib • Philadelphia chromosomewastheonsetoftargettherapyincancer In site http://the-medical-dictionary.com/imatinib_mesylate.htm

  18. Target Therapy SecondGeneration TKI Dasatinib Nilotinib Bosutinib DCC-2036 AP24534 AT9283

  19. References Almeida A, Castro I, Coutinho J, Guerra L, Marques H, Pereira AM. Recomendações para o Diagnóstico, Tratamento e Monitorização da Leucemia Mielóide Crónica. Acta MedPort 2009; 22: 537-544 Cayuela J-M, Macintyre E, Darlington M, Abdelali RB, Fund X, Villarese P, Tulliez M, Raffoux E, Sigaux F, Réa D, and Seror V. Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?. Haematologica 2011;96(5):664-671. Chauffaille ML. Análise citogenética e FISH no monitoramento da LMC em tratamento com inibidores da tirosinoquinase. Rev. Bras. Hematol. Hemoter. 2008, 30 (Imagem FIsh) Douglas, H; Robert A. W. – Hallmarks of Cancer: next generation. Elsevier. March 4, 2001. Druker B. J. [et al]. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase In the Blast Crisis of Chronic Myeloid Leukemia And Acute Lymphoblastic Leukemia With the Philadelphia Chromosome. N Engl J Med, Vol. 344, No. 14 April 5, 2001. Funke, V. et al (2010). Leucemia Mielóide Crónica e outra doenças mieloprofilerativas crónicas. Revista Brasileira de Hematologia e Hemoterapia. 32 (Supl.1):71-90. Goodsell D. S. The Molecular Perspective: c-Abl Tyrosine Kinase. The Oncologist 2005;10:758–759 Grando AC; Wagner SC. Avaliação laboratorial da doença residual mínima na leucemia mielóide crônica por Real-Time PCR. J BrasPatolMedLab. 2008, 44(6): 433-440 Griffiths, Anthony J. F. [et al]. Introdução à genética. 8ªedição. Rio de Janeiro: Guanabara-Koogan, 2006. Guttmacher A. E., Collins F. S. Molecular Diagnosis of the Hematologic Cancers. N Engl J Med 2003;348:1777-85. Hanahan D., Weinberg R. A. Hallmarks of Cancer: The Next Generation. Cell 144, March 4. Elsevier Inc, 2011. Harrison – Medicina Interna. 17ª Edição, vol.I:683-686. Hughes T, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. BLOOD. 2006, 108(1) 28-37 Knowles M., Selby P. Introduction to the Cellular and Molecular Biology of Cancer. 4 th ed. 2005, Oxford University Press. 189-193, 203-204, 219-226, 2005 Koo, H. (2011). Philadelphia Chromossome-Positive Acute Lymphoblastic Leukemia in Childhood. Korean J Pediatr. 54 (3): 106-110.

More Related